Replies to post #544369 on $Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

T/Y, still holding

[Tuff-Stuff]

Still holding some> The FDA's Endocrinologic and Metabolic Drugs Advisory Committee meets this Thursday to discuss Novo Nordisk's (NVO +2.3%) NDA for Saxenda (liraglutide) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of at least 30 kg/m2 (or a BMI of 27 kg/m2 in the presence of at least one weight-related comorbidity).
Novo markets liraglutide injection as Victoza for the treatment of type 2 diabetes in conjunction with diet and exercise.
Briefing docs